Kornimate/medical-research-clean huggingface dataset:
cannabidiol (cbd) and pediatric epilepsy

Conditions: Epilepsy

Summary: legislation to allow medical marijuana has had a significant impact on the pediatric population of colorado. there have been many reported different effects and properties of each of the over 60 known cannabinoids found in marijuana. the main exposures in pediatrics have involved the use of cannabidiol (cbd) high- and tetrahydrocannibinol (thc) low-content hash oil in children with epilepsy. the reported benefit of this oil is to have the anticonvulsant properties of cbd without the psychoactive components of thc. human studies on the efficacy of cbd on epilepsy are few and limited. the investigators' specific aims are the following: * specific aim 1: describe the plasma pharmacokinetics of cannabidiol (cbd), tetrahydrocannibinol (thc), and their respective metabolites in pediatric patients with epilepsy. * specific aim 2: describe the plasma pharmacokinetics of other antiepileptic drugs (aeds) taken in conjunction with cbd in order to evaluate drug interactions. * specific aim 3: describe parental perception of efficacy of cbd on control of epilepsy. the investigators will recruit children and their parents who are currently using or plan to use cbd for their seizure disorder. this study will not be providing patients with cbd. consenting subjects will undergo a number of blood and urine collection that will be analyzed to describe the pharmacokinetics and possible drug interactions of cbd in pediatric epilepsy.


Eligibility criteria:
inclusion criteria: * patients \> 1 month and \< 18 years of age who use, or plan to use, orally administered cbd rich hash oil for treatment of epilepsy * parent/legal guardian accompanying patient who is \>= 18 year of age and non-incarcerated. exclusion criteria: * patients without epilepsy/seizure disorder as diagnosed by a neurologist * have known abnormalities in liver (ast, alt, inr above normal range), or kidney function (creatinine above normal range) * patient is known to be pregnant at time of enrollment (however, guardians who may be pregnant can be included for survey completion) * patient is ward of the state * unable to provide verification of hash oil potency and content
to evaluate the efficacy and safety aliviador compared to gelol in patients with contusions, sprains, trauma and muscle injury.

Conditions: Contusions; Sprains; Trauma; Muscle Injury; Myalgia; Myofascial Pain; Tendinitis

Summary: multicenter, randomized, double-blind trial, to evaluate the efficacy and safety aliviador compared to gelol in the relief of signs and symptoms in patients with contusions, sprains, trauma and muscle injury start with less than 24 hours or patients of myalgia, myofascial pain and tendinitis.


Eligibility criteria:
inclusion criteria: * patients of both sexes, of any race, aged over 12 years. * ability to read, understand and sign the ic, in the case of minors consent of responsible; * clinical diagnosis of bruises, sprains, trauma, muscle damage occurred in less than 24 hours or muscle pain, myofascial pain or tendinitis. * patients able to understand and maintain the clinical protocol. exclusion criteria: * known hypersensitivity to components of the formulas of both the drug test as the comparator. * known hypersensitivity to paracetamol. * location of the lesion with skin wound or irritated. * liver or kidney disease known. * pregnant or lactating women. * patients who require surgery or immobilization. * patients with fractures or rupture of the ligaments. * patients using anticoagulants. * patients with severe concomitant systemic diseases, such as cancer, diabetes, or acquired heart disease, hematological diseases, seizure disorders, autoimmune diseases, renal failure, severe infections, hormonal disorders and pulmonary disorders. * history of alcoholism or illicit drug use; * use of nsaids, corticosteroids or venoterápicos, topics or any other form of administration. * conditions in the opinion of the researcher make the patient unsuitable to participate in the study.

Keywords: muscle injury
computer detection of diabetic retinopathy compared to clinical examination

Conditions: Diabetic Retinopathy

Summary: the hypothesis is that computer detection of the severity of diabetic retinopathy including the presence of clinically significant macular edema is not inferior to the detection using a dilated eye examination by a board-certified ophthalmologist.

the project is a multicenter, observational study to compare the accuracy of the idx-dr computer detection system to board certified ophthalmologists performing dilated eye examination at identifying between no or mild npdr without clinically significant diabetic macular edema from more than mild npdr with or without csdme. approximately 400-600 persons with diabetes will be recruited through 5 clinical centers. the ophthalmologist who examines the patient will evaluate and record the status of the eye based on his/her clinical examination. the study subjects will then have two fundus photographs taken of each eye. the photographic images will be transferred to a central reading center at the university of pennsylvania and interpreted by professional graders. the reading center will then transfer the images to idx-dr, the computer detection system. idx-llc, the sponsor of this study, will have no access to the images. data from the reading center interpretation will be considered the "gold standard". the results of the clinical examination and idx-dr will be compared against this gold standard as well as against each other.

Eligibility criteria:
inclusion criteria: * a diagnosis of diabetes mellitus * subject understands study and has signed informed consent * no history of any other retinal vascular disease, glaucoma, or other disease that may affect the appearance of the retina or optic disc (refractive error and ocular surface disease are allowed); * other than cataract surgery, no history of intraocular surgery, ocular laser treatments for any retinal disease, or ocular injections for diabetic macular edema or proliferative disease * no media opacity precluding good retinal photography * age 18 or older exclusion criteria: * no diagnosis of diabetes mellitus * potential subject cannot understand study or informed consent * a history of retinal vascular disease other than due to diabetic retinopathy, glaucoma, or other disease that may affect the appearance of the retina or optic disc * previous intraocular surgery other than cataract; previous laser to the retina; or previous intraocular injections for the treatment of diabetic retinopathy * a media opacity in either eye that is severe enough to preclude good retinal photography

Keywords: nonproliferative diabetic retinopathy diabetic macular edema proliferative diabetic retinopathy ophthalmologists dilated eye exam
comparing the efficacy of two methods for the therapy of uterine adhesion

Conditions: Intrauterine Adhesion

Summary: asherman's syndrome is characterized by the presence of intrauterine adhesions (iua) as well as symptoms such as amenorrhea, hypomenorrhea, pelvic pain, and infertility. the gold standard for the treatment of intrauterine adhesions is hysteroscopic intrauterine adhesions. the recurrence of intrauterine adhesions is a major challenge in clinical practice. it has been reported that dried biological aminion graft was used to prevent adhesion after the operation of intrauterine adhesions. intrauterine balloon can reduce the recurrence of adhesions after operation. does the combination of balloon and amniotic products can improve clinical outcomes? therefore, this study was conducted.

the diaposable balloon uterine(a special intrauterine balloon) is usually inserted into the uterine after a hysteroscopic adhesiolysis and removed after on the 7th day after surgery. another group, the diaposable balloon uterin and dried biological amnion will be inserted into the uterine after a hysteroscopic adhesiolysis and removed after on the 7th day after surgery.several investigators demonstrated its favorable effect in the recurrence of adhesion after the treatment of intrauterine adhesion. disposable balloon uterine stent is specially designed to fit into the cavity of the uterus, and usually removed on the 7th day after surgery. allocation: randomized endpoint classification: safety/efficacy study intervention model: parallel assignment masking: single blind (subject) primary purpose: prevention

Eligibility criteria:
inclusion criteria: * age 20-45 years. * previously diagnostic hysteroscopy confirmed adhesion score ≧5， according to the american fertility society (afs). * complains of menstruation disorder and reproductive dysfunction. * informed consent. exclusion criteria: * premature menopause, * presence of other intrauterine lesions (e.g. polyps, myoma, septa), and * presence of severe intercurrent illness (e.g. systemic disease, coagulative disorders, severe kidney and liver diseases), * adhesions limited to the lower uterine cavity or the cervical canal.

Keywords: asherman syndrome uterine stent hysteroscopy
a clinical trial of intensive dialysis

Conditions: Renal Replacement Therapy; Renal Dialysis; End Stage Kidney Disease; End Stage Renal Disease; Uremia

Summary: this study will assess clinical outcomes of extended weekly hours of haemodialysis (\>= 24 hours per week) compared with standard hours of haemodialysis (\<=18 hours/week) in people with eskd.

a rapidly increasing volume of observational data suggests substantial benefits may be associated with an increased duration of dialysis. as well as improved quality of life, improved functioning and beneficial changes in a variety of laboratory parameters, it has been suggested that extended dialysis sessions might reduce mortality and major morbidity. uncontrolled data from centres that have been providing extended dialysis shows dramatically lower mortality rates compared to those observed in centres providing standard duration dialysis. recent analyses of extended dialysis conclude that the savings achieved in drug and hospitalization costs may lead to an overall reduction in costs compared with traditional forms of dialysis. in this trial, we propose to examine the effects of extended dialysis (24 hours weekly or more) compared to standard dialysis (18 hours or less weekly) in patients with eskd. the proposed study is a multi-centre, open label, randomised, controlled trial. the study began with a pilot phase which was converted to the current main study on the receipt of peer-reviewed funding for the full study.

Eligibility criteria:
inclusion criteria: 1. incident or prevalent patients requiring maintenance haemodialysis therapy for eskd 2. aged 18 years or older 3. undergoing dialysis for 18 hours per week or less 4. suitable for either extended or standard dialysis in the view of the treating physician 5. agreeable to randomisation exclusion criteria: 1. life expectancy of less than 6 months 2. definite plans to undergo renal transplantation within 12 months of entry to the study 3. inability to complete quality of life questionnaire 4. concomitant major illness that would limit assessments and followup 5. high chance that the patient will not adhere to study treatment and follow up in the view of the treating physician.

Keywords: randomized controlled trial clinical trial controlled clinical trial clinical trial, phase iv multicenter study end stage kidney disease hemodialysis renal dialysis renal replacement therapy nocturnal dialysis extended dialysis quality of life quality adjusted life year hypertrophy, left ventricular blood pressure hypertension anemia hematinics erythropoiesis stimulating agents cost-utility analysis economic evaluation health care utilisation health care costs health expenditures hospitalization cost analysis cardiovascular diseases acute coronary syndrome myocardial infarction stroke cerebrovascular disorders mortality arteriovenous fistula arteriovenous shunt, surgical thrombosis infection
a study of minirin melt in patients with nocturia

Conditions: Nocturia

Summary: this is a confirmation of safety profile for minirin melt in clinical practice.


Eligibility criteria:
inclusion criteria: * patients suffering from nocturia exclusion criteria: * habitual or psychogenic polydipsia * known or suspected cardiac insufficiency and other conditions requiring treatment with diuretics * moderate and severe renal insufficiency * know hyponatremia * syndrome of inappropriate adh secretion
clinical study of 18f-fapi-rgd pet/ct in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the goal of this observational study is to learn about 18f-fapi-rgd pet/ct imaging in assessing rheumatoid arthritis disease activity. participants will undergo clinical evaluation and 18f-fapi-rgd pet/ct examination.

patients with rheumatoid arthritis who met the 2010 american college of rheumatology/european league against rheumatism rheumatoid arthritis classification criteria will be included. all patients will be assessed for disease activity and the clinical disease activity index (cdai) was calculated. blood sedimentation rate and crp assay results will be collected. all patients will undergo 18f-fapi-rgd pet/ct examination. the correlation of cdai, esr and crp levels with pet joint count and pet joint index as measured by 18f-fapi-rgd pet/ct will be statistically analyzed.

Eligibility criteria:
inclusion criteria: * patients with rheumatoid arthritis who meet the 2010 american college of rheumatology/european league against rheumatism rheumatoid arthritis classification criteria. exclusion criteria: * a. patients with malignant tumors and other rheumatic immune diseases; b. clinical and conventional radiographic inspection of materials; c. researchers think not suitable for other information to participate in this study.
tearlab core validation study to establish referent values for dry eye disease

Conditions: Keratoconjunctivitis Sicca

Summary: this is a prospective, observational case series to determine the clinical utility of tear osmolarity and other commonly used objective tests to diagnose dry eye disease, as well as to establish referent values for objective tests of the disease.

this is a prospective, observational case series to determine the clinical utility of tear osmolarity, tear film breakup time, corneal fluorescein staining, conjunctival lissamine green staining, schirmer's test without anesthesia, bron/foulks meibomian glan grading and the ocular surface disease index to diagnose dry eye disease, as well as to establish referent values for objective tests of the disease. patients were recruited across sites in the eu and us from the general clinical population.

Eligibility criteria:
inclusion criteria: * be between the ages of 18 and 79 years of age. * must understand and be able, willing and likely to fully comply with study procedures and restrictions. exclusion criteria: * clinically significant eyelid deformity or eyelid movement disorder that is caused by conditions such as notch deformity, incomplete lid closure, entropion, ectropion, hordeola or chalazia.. * previous ocular disease leaving sequelae or requiring current topical eye therapy other than for dry eye disease, including, but not limited to: active corneal or conjunctival infection of the eye and ocular surface scarring. * active ocular allergy. * lasik or prk surgery that was performed within one year of visit 1. * started or changed the dose of chronic ocular medication within 30 days of visit 1. * contact lens worn within the past eight (8) hours. * any ophthalmologic drops within 2 hours of screening and visit 1 procedures. * pregnancy or lactation. * abnormality of nasolacrimal drainage (by history). * punctual plugs placement or cauterization within 30 days of visit 1 * started or changed the dose of chronic systemic medication known to affect tear production including, but not limited to antihistamines, antidepressants, diuretics, corticosteroids or immunomodulators within 30 days of visit 1. * systemic disease known to affect tear production or loss including, but not limited to thyroid eye disease, that has been diagnosed or has not been stable within 30 days of visit 1. * known hypersensitivity to any of the agents used in testing i.e. sodium fluorescein, lissamine green, oxybuprocaine or proparacaine.

Keywords: dry eye disease dry eye syndrome dry eye
comparing imaginal exposure and imagery rescripting in treatment of posttraumatic stress disorder (ptsd)

Conditions: Posttraumatic Stress Disorder

Summary: the outcome of trauma treatment (posttraumatic stress disorder - ptsd) may be influenced by which emotions that are predominant among current symptoms, e.g. fear, anger, guilt, shame. different treatment procedures for processing traumatic memories may resolve different emotions. this study compares two different treatment procedures of working with trauma memories in ptsd treatment (namely, imaginal exposure and imagery rescripting) in order to test this.

the main objectives of this study are: 1. to assess the relative efficacy of the two procedures in inpatient treatment for ptsd 2. to assess whether the predominant emotions in the traumatic memories moderate the outcome of the different procedures 3. to assess whether theory-derived constructs mediate outcome and whether the mediating relationships are different in the two treatments 4. to provide a theoretical account of the two models 5. to psychometrically evaluate 3 new measures

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of ptsd identified as primary diagnosis * accepts withdrawal of all psychotropic medication exclusion criteria: * extensive dissociative symptoms or current psychosis, * current suicidal risk, * extensive current substance or alcohol abuse, or * ongoing trauma
a study of the safety, pk, and exploratory efficacy of sp-624 in acutely psychotic adult subjects with schizophrenia

Conditions: Schizophrenia

Summary: this is a phase 1b clinical study evaluating the safety and exploring the effectiveness of sp-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.


Eligibility criteria:
key inclusion criteria: * is willing and able to provide written informed consent to participate in the study. * has an identified reliable informant. * is, in the investigator's opinion, suitable for initiating a washout from the subject's current antipsychotic regimen, if applicable, and is willing to abstain from prohibited psychotropic medications in accordance with study requirements. * subjects must meet screening eligibility criteria and be in an inpatient setting prior to discontinuing antipsychotic medications. * subject must be able, in the investigator's opinion, to safely discontinue prohibited psychotropic medications prior to baseline without increased suicidality. * has a primary diagnosis of schizophrenia based on the diagnostic and statistical manual 5th edition (dsm-5) criteria and confirmed by mini international neuropsychiatric interview (mini) for psychotic disorders studies. * is experiencing an acute exacerbation or relapse of symptoms. * is in generally good physical health, in the investigator's opinion, based on screening medical history, physical examination, vital signs, and clinical laboratory values. * has a body mass index (bmi) between 18 and 40 kg/m2, inclusive. * for women of reproductive potential: has a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline. * for women of reproductive potential and men with female partners of reproductive potential: agrees to remain abstinent from sexual intercourse or use adequate and reliable contraception throughout the study and for at least 30 days after the last dose of study drug. key exclusion criteria: * is a woman who is pregnant, breastfeeding, or less than 6 months postpartum at screening. * has any primary dsm-5 disorder other than schizophrenia, as confirmed by the mini. * fails to discontinue prohibited psychotropic medications. * has, in the investigator's opinion, a significant risk of violent or destructive behavior. * is currently hospitalized involuntarily or incarcerated. * has a history or presence of any clinically significant medical condition, disease, or surgical history that could, in the investigator's opinion, jeopardize the safety of the subject or validity of the study data, or interfere with the absorption, distribution, metabolism, or excretion of the study drug. * is, in the investigator's opinion, not a suitable candidate for the study.
accurate controlled dental sedation

Conditions: Mental Retardation

Summary: the aim of this study is to evaluate benefits of the method of dental sedation using target controlled infusion (tci) combined with bispectral index (bis) monitoring in patients with mental retardation and challenging behavior.

the intravenous sedation of using of propofol is very effective for dental patients with mental retardation and challenging behavior. however, it is very difficult to titrate the dose of propofol for maintaining the adequate sedative depth because of the difficulty of verbal communication with them. therefore, the infusion of excessive propofol dose elicits the complications and delay of recovery.

Eligibility criteria:
inclusion criteria: 1. participants aged 16 or over, 2. american society of anesthesiologists (asa) physical status 1 or 2 3. the treatments of dental caries, endodontics, periodontics and prosthesis were planed 4. participants had moderate or severe mental retardation, and were not completely cooperated with dental treatment exclusion criteria: 1. patients could communicate and cooperate with dental treatment, but used dental sedation for decrease of the anxiety and the fear about dental treatment or another reasons, 2. patients needed premedication 3. patients had uncontrolled or sever medical condition

Keywords: intravenous sedation target controlled infusion bispectral index dental treatment mental retardation deep sedation
correlation between preeclampsia and positive for obstructive sleep apnea screening test: stopbang questionnaire

Conditions: Sleep Apnea, Obstructive

Summary: the purpose of this study is to find the correlation between high risk osa (obstructive sleep apnea) patient, based on stop-bang screening tool and preeclampsia

obstructive sleep apnea (osa) has been associated with preeclampsia and intrauterine growth retardation (iugr). since the gold standard diagnosis of osa is polysomnogram which is limited by cost and availability. therefore, various screening tools were proposed in order to identify high risk osa patient such as stop-bang questionnaire. from the previous study, stop-bang showed a high predictive performance and the score equal or higher than 3 determines high risk for osa.

Eligibility criteria:
inclusion criteria: - pregnant women who were scheduled for cesarean delivery or admitted to the antepartum unit at ramathibodi hospital exclusion criteria: * age \< 18 year old * previous diagnose osa * patients who have used continuous positive airway pressure (cpap) or bi-level positive airway pressure (bi-pap) fro osa treatment

Keywords: obstructive sleep apnea preeclampsia pregnancy stopbang
prevalence of postpartum depression in hospital jose e. gonzalez

Conditions: Postpartum Depression

Summary: this research will use the edinburgh scale of post partum depression to evaluate patients during their 4th to 6th after delivery, and the investigators will compare the results with those found in other countries with population with similar characteristics as ours


Eligibility criteria:
inclusion criteria: * patients on their 4th -6th week after delivery, who gave birth in our institution exclusion criteria: * patients with previous diagnosis of psychiatric pathology

Keywords: postpartum depression edinburgh postpartum depression scale mexican population